Immuron Announces Travelan® Clinical Study Cohort 2 commences
18 oct. 2023 06h00 HE
|
Immuron Limited
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
25 juil. 2023 06h00 HE
|
Immuron Limited
Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron Business Update - Ateria Health launches Juvia™ in Australia
11 juil. 2023 06h00 HE
|
Immuron Limited
Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in AustraliaNew clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to...
Immuron Initiates Recruitment of Travelan® Clinical Study
30 mai 2023 06h00 HE
|
Immuron Limited
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
08 mai 2023 06h00 HE
|
Immuron Limited
Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily...
Immuron Submits IND Application To FDA for Travelan
05 déc. 2022 06h00 HE
|
Immuron Limited
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
04 oct. 2022 06h00 HE
|
Immuron Limited
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
15 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
US DoD Naval Medical Research Center Clinical Update
10 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
Immuron Travelers’ Diarrhea Market Update
12 oct. 2020 06h00 HE
|
Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...